AustriaThe German agricultural chemical and pharmaceutical company Bayer has spun off its U.S. business involving the controversial herbicide Glyphosate into a separate entity called Ruveon. This move aims to better align the business with the specific demands of the U.S. market, focusing on pricing, production, and logistics. Ruveon will remain part of the Bayer group but operate independently to respond more agilely to competition from generic products. Bayer has faced a multi-billion-dollar wave of lawsuits in the U.S. over potential cancer risks associated with its glyphosate-based weed killer Roundup. In February, Bayer reached a preliminary agreement to settle these legal disputes for $7.25 billion (approximately €6.4 billion), with a final approval hearing scheduled for August. Recently, Bayer achieved a significant legal victory at the highest U.S. court, which ruled that companies cannot be sued for failing to include cancer warnings on herbicide packaging. This decision could invalidate thousands of Roundup-related lawsuits. Bayer denies any cancer risk linked to Roundup.
Bias read (Center): The article presents factual information about Bayer's corporate restructuring and legal challenges related to Glyphosate and Roundup. It includes both Bayer's statements and legal developments without overtly favoring one side. The framing remains neutral, focusing on corporate strategy and legal裁决
